Featured Research

from universities, journals, and other organizations

Many new drugs did not have comparative effectiveness information available at time of FDA approval, study finds

Date:
May 4, 2011
Source:
JAMA and Archives Journals
Summary:
Only about half of new drugs approved in the last decade had comparative effectiveness data available at the time of their approval by the US Food and Drug Administration, and approximately two-thirds of new drugs had this information available when alternative treatment options existed, according to a new study.

Only about half of new drugs approved in the last decade had comparative effectiveness data available at the time of their approval by the U.S. Food and Drug Administration, and approximately two-thirds of new drugs had this information available when alternative treatment options existed, according to a study in the May 4 issue of JAMA.

In 2009, Congress allocated $1.1 billion to comparative effectiveness research. According to the Institute of Medicine, such research is defined as the "generation and synthesis of evidence that compares the benefits and harms of alternative methods to prevent, diagnose, treat, and monitor a clinical condition or to improve the delivery of care." Comparative effectiveness information on drugs is most useful to decision-makers shortly after marketing approval, when observational data from routine care and data from large head-to-head trials comparing multiple treatments are not yet available. "Comparative effectiveness is taking on an increasingly important role in U.S. health care, yet little is known about the availability of comparative efficacy data for drugs at the time of their approval in the United States," according to background information in the study.

Nikolas H. Goldberg, and colleagues from Brigham and Women's Hospital and Harvard Medical School, Boston, conducted a study to determine the proportion of recently approved drugs that had comparative efficacy data available at the time of market authorization in the United States and to examine trends in availability of this information over time and by therapeutic indication. Data for the study were derived from approval packages publicly available through the online database of drug products (new molecular entities [NMEs]) approved by the U.S. Food and Drug Administration (FDA) between 2000 and 2010. The researchers analyzed whether eligible efficacy studies were head-to-head active controlled trials and whether the results of such studies were available in the approval packages.

The authors identified 197 eligible approved NMEs between 2000 and 2010, of which 100 (51 percent) had comparative efficacy data available at the time of market authorization. After excluding orphan products (n = 37; products or drugs that may be useful for common or rare diseases but which are not considered commercially viable) and other NMEs approved for indications for which no alternative treatments existed (n= 17), the proportion with available comparative efficacy data increased to 70 percent. On a yearly basis, the proportion of NMEs with comparative efficacy data (excluding orphan drugs and those for which no alternative treatment existed) varied between 50 percent in 2008 and 92 percent in 2010.

The researchers found that availability of comparative efficacy data was more common for some therapeutic indications, including diabetes mellitus (89 percent) and infectious diseases (73 percent), than others, such as hormones and contraceptives (33 percent), and cancer (35 percent). After excluding orphan drugs and products approved for indications for which no alternative treatments existed, the proportions by therapeutic indications were more similar. The authors also found that compared with those drugs that received standard review designations, NMEs that received priority review designations were much less likely to have comparative efficacy data.

The researchers note that although comparative efficacy data meeting their minimal criteria were available for approximately half of all newly approved NMEs, they did not assess the extent to which the publicly available data are informative enough to provide a basis for prescribing and coverage decisions.

"In conclusion, we found that publicly available documents include results of at least 1 head-to-head trial with an approved alternative for approximately half of all newly approved NMEs. Strategies are needed to enhance the accessibility of, and ultimately the use of, this information, particularly in the early marketing experience, when comparative effectiveness data from other sources are scarce or nonexistent."


Story Source:

The above story is based on materials provided by JAMA and Archives Journals. Note: Materials may be edited for content and length.


Journal Reference:

  1. Nikolas H. Goldberg, Sebastian Schneeweiss, Mary K. Kowal, Joshua J. Gagne. Availability of Comparative Efficacy Data at the Time of Drug Approval in the United States. JAMA, 2011; 305 (17): 1786-1789 DOI: 10.1001/jama.2011.539

Cite This Page:

JAMA and Archives Journals. "Many new drugs did not have comparative effectiveness information available at time of FDA approval, study finds." ScienceDaily. ScienceDaily, 4 May 2011. <www.sciencedaily.com/releases/2011/05/110503161400.htm>.
JAMA and Archives Journals. (2011, May 4). Many new drugs did not have comparative effectiveness information available at time of FDA approval, study finds. ScienceDaily. Retrieved September 2, 2014 from www.sciencedaily.com/releases/2011/05/110503161400.htm
JAMA and Archives Journals. "Many new drugs did not have comparative effectiveness information available at time of FDA approval, study finds." ScienceDaily. www.sciencedaily.com/releases/2011/05/110503161400.htm (accessed September 2, 2014).

Share This




More Health & Medicine News

Tuesday, September 2, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Get on Your Bike! London Cycling Popularity Soars Despite Danger

Get on Your Bike! London Cycling Popularity Soars Despite Danger

AFP (Sep. 1, 2014) Wedged between buses, lorries and cars, cycling in London isn't for the faint hearted. Nevertheless the number of people choosing to bike in the British capital has doubled over the past 15 years. Duration: 02:27 Video provided by AFP
Powered by NewsLook.com
Can You Train Your Brain To Eat Healthy?

Can You Train Your Brain To Eat Healthy?

Newsy (Sep. 1, 2014) New research says if you condition yourself to eat healthy foods, eventually you'll crave them instead of junk food. Video provided by Newsy
Powered by NewsLook.com
We've Got Mites Living In Our Faces And So Do You

We've Got Mites Living In Our Faces And So Do You

Newsy (Aug. 30, 2014) A new study suggests 100 percent of adult humans (those over 18 years of age) have Demodex mites living in their faces. Video provided by Newsy
Powered by NewsLook.com
Liberia Continues Fight Against Ebola

Liberia Continues Fight Against Ebola

AFP (Aug. 30, 2014) Authorities in Liberia try to stem the spread of the Ebola epidemic by raising awareness and setting up sanitation units for people to wash their hands. Duration: 00:41 Video provided by AFP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins